← Leaderboards
Scott G Kitchen
University Of California Los Angeles
$17,099,191
Attributed
$21,810,683
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,074,825 · 22
By mechanism
U19$20,877,889 · 8
R01$9,332,482 · 4
P30$1,876,926 · 3
R33$1,552,942 · 1
R21$1,340,218 · 3
P01$750,624 · 2
Top collaborators
- Irvin S.Y. Chen10 shared
- Hans-Peter Kiem5 shared
- Nathaniel R. Landau5 shared
- Otto O Yang5 shared
- Anjie Zhen5 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Tom Chou$3,256,777
- Irvin S.y. Chen$31,294,828
- Christopher J Evans$13,104,202
- Otto O Yang$29,888,904
- Stephen H Tsang$18,411,197
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInfectionImmuneImmune SystemIn VivoHiv InfectionsHumanized MouseMouse ModelT-LymphocyteHiv-1ResponseTissuesViralVirus DiseasesBaseMalignant NeoplasmsVirusAnimal ModelEngraftmentPlayAnimalsPreventPathogenesisGene Therapy
Grant awards (70)
Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection$343,744
R34 · FY2025 · AI · contact PI
Core D -Humanized Mouse and Gene Therapy Core$134,802
P30 · FY2025 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,848,211
U19 · FY2024 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$776,131
R01 · FY2024 · AI
Core-002$490,362
U19 · FY2024 · AI · contact PI
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection$370,500
R01 · FY2024 · DA
Core-001$276,585
U19 · FY2024 · AI · contact PI
Project-002$158,034
U19 · FY2024 · AI · contact PI
Core D -Humanized Mouse and Gene Therapy Core$124,195
P30 · FY2024 · AI · contact PI
Admin-Core-001$75,492
U19 · FY2024 · AI · contact PI
Project-003$40,013
U19 · FY2024 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,848,126
U19 · FY2023 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2023 · AI
Enhancing HSPC CAR-mediated immunity in vivo$451,537
U19 · FY2023 · AI · contact PI
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection$370,500
R01 · FY2023 · DA
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$312,000
R01 · FY2023 · CA · contact PI
Core D -Humanized Mouse and Gene Therapy Core$139,757
P30 · FY2023 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,847,671
U19 · FY2022 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2022 · AI
Enhancing HSPC CAR-mediated immunity in vivo$475,999
U19 · FY2022 · AI · contact PI
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection$370,500
R01 · FY2022 · DA
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$312,000
R01 · FY2022 · CA · contact PI
Core D -Humanized Mouse and Gene Therapy Core$138,337
P30 · FY2022 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,847,927
U19 · FY2021 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2021 · AI
Enhancing HSPC CAR-mediated immunity in vivo$456,689
U19 · FY2021 · AI · contact PI
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection$370,500
R01 · FY2021 · DA
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$312,000
R01 · FY2021 · CA · contact PI
Mouse Core$146,444
P01 · FY2021 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,872,207
U19 · FY2020 · AI · contact PI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery$768,331
R01 · FY2020 · AI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$504,970
R33 · FY2020 · AI
Enhancing HSPC CAR-mediated immunity in vivo$468,000
U19 · FY2020 · AI · contact PI
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection$370,500
R01 · FY2020 · DA
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$312,000
R01 · FY2020 · CA · contact PI
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$195,000
R01 · FY2020 · CA · contact PI
Mouse Core$147,113
P01 · FY2020 · AI · contact PI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo$807,216
U19 · FY2019 · AI · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$506,210
R33 · FY2019 · AI
Role of persistent type I IFN signaling in immune suppression and tumorigenesis during chronic HIV infection$312,000
R01 · FY2019 · CA · contact PI
Mouse Core$150,543
P01 · FY2019 · AI · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$541,762
R33 · FY2018 · AI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo$434,455
U19 · FY2018 · AI · contact PI
Mouse Core$152,523
P01 · FY2018 · AI · contact PI
Humanized Mouse Chimera Core$128,947
P30 · FY2018 · AI · contact PI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo$676,680
U19 · FY2017 · AI · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$217,685
R21 · FY2017 · AI
Mouse Core$154,001
P01 · FY2017 · AI · contact PI
Humanized Mouse Chimera Core$131,084
P30 · FY2017 · AI · contact PI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo$997,645
U19 · FY2016 · AI · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$239,781
R21 · FY2016 · AI
Humanized Mouse Chimera Core$131,194
P30 · FY2016 · AI · contact PI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo$805,040
U19 · FY2015 · AI · contact PI
Targeting Type I Interferon Immune Activation to Control HIV Infection in vivo$192,500
R21 · FY2015 · AI · contact PI
Humanized Mouse Chimera Core$131,355
P30 · FY2015 · AI · contact PI
Targeting Type I Interferon Immune Activation to Control HIV Infection in vivo$231,000
R21 · FY2014 · AI · contact PI
Humanized Mouse Chimera Core$136,054
P30 · FY2014 · AI · contact PI
The role of CD4 in macrophage differentiation and function$354,699
R01 · FY2013 · AI · contact PI
Humanized Mouse Chimera Core$132,270
P30 · FY2013 · AI · contact PI
The role of CD4 in macrophage differentiation and function$377,339
R01 · FY2012 · AI · contact PI
Mouse/Human Chimera Core$130,989
P30 · FY2012 · AI · contact PI
The role of CD4 in macrophage differentiation and function$377,339
R01 · FY2011 · AI · contact PI
Mouse/Human Chimera Core$172,361
P30 · FY2011 · AI · contact PI
The role of CD4 in macrophage differentiation and function$381,150
R01 · FY2010 · AI · contact PI
Mouse/Human Chimera Core$87,352
P30 · FY2010 · AI · contact PI
The role of CD4 in macrophage differentiation and function$385,000
R01 · FY2009 · AI · contact PI
Mouse/Human Chimera Core$82,177
P30 · FY2009 · AI · contact PI
Mouse/Human Chimera Core$76,052
P30 · FY2008 · AI · contact PI
The Role of CD8 on CD4+ T Cells$230,376
R21 · FY2004 · AI
The Role of CD8 on CD4+ T Cells$228,876
R21 · FY2003 · AI